2023 World Conference on Lung Cancer (Posters)-P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy

P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy - PDF(Slides)

Back to course

Pdf Summary

This document outlines a study design for the treatment of leptomeningeal metastasis (LM) in patients with EGFR-mutated lung adenocarcinoma and symptomatic epilepsy. The traditional methods of treatment, such as intrathecal injection of chemotherapeutic drugs and whole brain radiotherapy, have limited efficacy and high toxicity. The study aims to evaluate the clinical efficacy of combining aumolertinib, a third-generation EGFR-TKI, with intrathecal pemetrexed, a chemotherapeutic drug, for the treatment of LM in patients who have progressed after first- and second-generation EGFR-TKIs. The study also aims to investigate the effect of the antiepileptic drug carbamazepine when used in combination with aumolertinib and intrathecal pemetrexed. This combination therapy will be evaluated in a phase II clinical trial with 20-25 patients. The primary endpoints of the study are median overall survival and the control rate of anti-epileptic treatment. Secondary endpoints include safety, progression-free survival, and objective response rate. Additionally, the study will conduct whole-exome sequencing comparison technology to study changes in cerebrospinal fluid gene detection and explore tumor heterogeneity and molecular mechanisms of LM at the gene level. The study aims to provide a new treatment plan for LM patients with symptomatic epilepsy and offer a more reasonable basis for the combination of drugs in these patients.

Asset Subtitle

Li Li

Meta Tag

Speaker Li Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

leptomeningeal metastasis

EGFR-mutated lung adenocarcinoma

symptomatic epilepsy

intrathecal injection

chemotherapeutic drugs

aumolertinib

intrathecal pemetrexed

carbamazepine

phase II clinical trial

whole-exome sequencing